A phase III randomised trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck

The Liverpool Head and Neck Oncology Group

Summary We describe a phase III trial on 200 patients with end stage squamous cell carcinoma of the head and neck. The patients were randomised to one of four treatment arms: cisplatinum alone, methotrexate alone, cisplatinum + 5-FU and cisplatinum + methotrexate. There was no significant difference in the response rates, but the survival of the cisplatinum arm was significantly better than that of the methotrexate arm. The survival of patients receiving cisplatinum as a single agent was longer than that of patients receiving cisplatinum in combination with methotrexate or 5-FU, but not significantly so. Nausea/vomiting and anaemia were significantly more common in the cisplatinum arms than in the methotrexate arm, but the toxicity of combination regimens was not significantly greater than that of cisplatinum used as a single agent.

Chemotherapy can be used in the treatment of squamous carcinoma of the head and neck, either as an adjuvant to surgery or radiotherapy, or for the sole treatment of end stage disease (that is advanced or recurrent tumours).

Methotrexate was previously regarded as the standard chemotherapeutic agent for end stage disease and its dosage and mode of administration have been extensively investigated in phase II studies. Weekly administration of 40–60 mg m⁻² produces the best response rates; higher dosage and/or more frequent administration does not improve the rate or duration of response (Muggia et al., 1980).

Cisplatinum has been shown to have antitumour activity in squamous cell carcinoma of the head and neck (Jacobs et al., 1980; Wittes et al., 1979). In one of the few randomised trials undertaken cisplatinum achieved similar response rates (23.5% and 28.6% respectively) to methotrexate in patients with recurrent head and neck cancer (Hong et al., 1983).

Several studies using combination chemotherapy suggest that cisplatinum in combination is superior to cisplatinum alone. High dose bolus cisplatinum plus 120 h continuous infusion of 5-fluorouracil every 3 weeks achieves a 70% objective response rate (26% complete responses) in end stage disease (Decker et al., 1983; Kish et al., 1984). The importance of the timing is also emphasised. In a randomised study using equitoxic doses of cisplatinum and 5-FU, cisplatinum as a continuous infusion produced a 72% response rate, but when given as a bolus injection on days 1 and 8 the response rate dropped to 20% (Kish et al., 1985).

Only two randomised trials have been conducted to assess the value of cisplatinum as a single agent compared with cisplatinum in combination. A previous prospective randomised trial carried out in this department on end stage patients compared cisplatinum, bleomycin, cisplatinum + bleomycin and a control untreated group (Morton et al., 1985).

Although there was no significant difference in the response rates of the three treated arms, cisplatinum as a single agent significantly prolonged the median survival time compared with the other groups. A randomised phase III trial of cisplatinum with and without methotrexate showed that methotrexate merely increased the toxicity but not the survival (Jacobs et al., 1983).

We now report a prospective randomised phase III trial comparing cisplatinum, methotrexate, cisplatinum + 5-fluorouracil and cisplatinum + methotrexate. There was no control (untreated) arm as we have already shown that cisplatinum as a single agent significantly prolongs survival in this group of patients (Morton et al., 1985).

Patients and methods

Patients

Patients with histologically proven end stage squamous cell carcinoma of the head and neck that was unsuitable for treatment with surgery or radiotherapy were admitted to this trial. End stage disease is defined as disease which is too advanced for treatment by radiotherapy or surgery, or disease which has recurred after prior radiotherapy and/or surgery.

Seventy-one patients had received no prior treatment; 129 patients had an untreated recurrence after prior radiotherapy and/or surgery. No patient had had prior chemotherapy. Two hundred such patients were admitted between May 1984 and November 1987.

The patients' tumour was classified using the site and stage groupings recommended by the UICC(UICC, 1987). Forty-five patients with recurrent tumour solely in the neck could not be assigned a stage group because of the absence of a primary tumour.

The patients' performance status was classified by Karnofsky's criteria (Karnofsky & Buckenall, 1949). The data are shown in Table I.

Pretreatment assessment

This included classification of each tumour by site and stage according to the UICC classification, assessment of the patient's general condition and Karnofsky performance status, complete physical examination, routine haematological and biochemical screening, liver function tests, 24 h creatinine clearance, chest radiograph, ECG and pure tone audiometry. Other appropriate investigations were carried out in specific cases, including CT scan, bone scan, etc. Every patient was assessed by the same consultant physician, who advised also on any medical problems encountered during the trial.

Randomisation

The method of 'intention to treat' was followed, i.e. first all patients presenting with end stage disease were randomised to the various treatment groups before assessment of fitness and obtaining of consent; second no patient was withdrawn from analysis once he had been randomised, even if he

Chairman: P.M. Stell.
Members: R.S. Allison, J.B. Campbell, J.E. Dalby, E.B. Dorman, T.R. Helliiwell, K. van Laer, R.P. Morton, F. Rugman, M.Z. Siodlak, M. Squadrelli and J.A. Wilson
Correspondence: P.M. Stell, Dept of Otorhinolaryngology, Royal Liverpool Hospital, Prescot Street, PO Box 147, Liverpool L69 3BX, UK.
Received 16 January 1989; and in revised form 7 June 1989.

© Macmillan Press Ltd., 1990
refused, or was unfit, to receive chemotherapy. The patients were randomised between the four arms by drawing cards from a bag. Fifty patients were admitted to each arm: calculation showed that this number will detect a three month prolongation of median survival in this group of patients, with a type 1 error of 5% and a type II error of 20%. Stratification for prognostic factors was not used.

**Dosage and administration**

Cisplatinum was given by the same method and at the same dose, in all the three cisplatinum arms: the patients were prehydrated with 2 litres of normal saline over 16 h, followed immediately by infusion of cisplatinum at 100 mg m\(^{-2}\) plus 12.5 g of mannitol, in 1 litre of normal saline over 8 h. During the infusion of cisplatinum, patients were given Maxol- on (metoclopramide) at 5 mg kg\(^{-1}\) diluted in 500 ml of normal saline. The cisplatinum infusion was stopped for 15 min every 2 h while the Maxolon infusion was given. Following the cisplatinum the patients were post-hydrated with 1 litre of normal saline in 8 h.

Methotrexate was given by intravenous bolus injection, at a dose of 40 mg m\(^{-2}\). 5-Fluorouracil was given at a dose of 1000 mg m\(^{-2}\) for 4 days as a continuous infusion, each day’s dose being given in 2 litres of normal saline. This infusion followed the cisplatinum immediately and replaced the post-hydration.

All of the cisplatinum containing regimens were repeated at monthly intervals, whereas methotrexate was given every 2 weeks.

**Assessment during the trial**

During treatment we attempted to see all patients at 2-weekly intervals to assess the response, the patients’ general condition and any specific symptoms, and to alter any medications. An FBC and an SMA (urea, electrolytes and LFTs) were done on all patients. In addition to this patients receiving cisplatinum had a chest X-ray, ECG, pure tone audiometry and 24 h urine creatinine clearance before each course of treatment. If the creatinine clearance fell to between 50 and 60 ml min\(^{-1}\) the dose of cisplatinum was reduced to 50 mg m\(^{-2}\). If it fell below 50 ml min\(^{-1}\) treatment was postponed until the creatinine clearance returned to normal. Treatment was not given when the haematological indices were unsatisfactory.

**Cessation of treatment**

Treatment was discontinued, with the patient’s consent, if there was no evidence of response after three cycles, with the development of major toxicity or at the patient’s own request.

**Assessment of response**

The WHO definition of response was used (Miller et al., 1981). Accessible lesions of the mouth and nodes in the neck were measured by calipers. Assessment of laryngeal and hypopharyngeal lesions was mainly based on clinical examination. Lesions of the nose, sinus, nasopharynx and ear were assessed by radiology.

**Toxicity**

Toxicity was assessed after each course of chemotherapy. The data are displayed according to the WHO criteria (Miller et al., 1981).

**Informed consent**

Ethical committee approval was obtained for the trial. The trial, its purpose and side-effects of the chemotherapy were discussed fully with each patient and his or her relatives.

**Follow-up and analysis of the data**

The exact date of death of those who have died is known either from personal follow-up or from the Mersey Region Cancer Registry. The status of the patients who are alive has been checked within, at most, the past 6 weeks. No patient has been lost to follow-up.

Qualitative data are displayed in contingency tables and analysed by \(\chi^2\). Survival is presented by the Kaplan–Meier method (Kaplan & Meier, 1985). Differences between survival curves were analysed by the log rank test (Peto et al., 1976). Prognostic factors were identified by Cox’s regression analysis (Cox, 1972).

**Results**

**Response rate**

The response rates are shown in Table II. The response rate for the whole group was 21.5%, and for treated patients was 27.8%. There was no significant difference in the response rate between the various arms, either of the whole group (\(\chi^2 = 14.42\)) or of the treated group (\(\chi^2 = 6.99\)). The response rate for previously untreated patients was 35% (19/55).
Survival

Figure 1 shows the survival curve for the four treatment groups: the cisplatin arm had a significantly better survival than the methotrexate arm ($X^2_1 = 5.53, P<0.025$). The survival of those receiving cisplatinum in combination with methotrexate or 5-FU was worse than that of those receiving cisplatinum alone, but the differences were not significant ($X^2_1 = 1.95, X^2_1 = 0.81$ resp.). The survival of those patients receiving cisplatinum plus methotrexate was only slightly better than that of those receiving methotrexate alone, and the difference was not significant ($X^2_1 = 0.77$).

The median survival for various host, tumour and treatment factors is shown in Table III. Univariate analysis using the log rank method showed that performance status and response were significant factors, whereas age, sex, histological grade, site and previous treatment were not. Analysis for trend confirmed that the trend of improving survival with higher rates of Karnofsky status was also highly significant ($X^2_1 = 46.6, P<0.001$). Almost all patients were in stage IV so that analysis for different stage groups was not done.

The data were then submitted to Cox's multivariate regression analysis, which confirmed that only two prognostic factors had a significant effect on survival: Karnofsky status and response to chemotherapy (Table IV). The effect of previous treatment was not quite significant ($P=0.07$). This analysis also confirmed that cisplatin was better than methotrexate ($z = 2.18, P<0.05$), whereas those patients receiving cisplatin plus 5-FU or cisplatin plus methotrexate did not do significantly better than those patients receiving methotrexate alone ($z = 1.07$, and $z = 1.53$ respectively).

Toxicity

Nausea, vomiting and renal toxicity caused by the cisplatin containing regimens were the major problems. Mild nausea and vomiting (WHO 1–2) affected approximately one third of the patients receiving cisplatin (Table V) alone or in combination, and severe nausea and vomiting (WHO 3–4) in 22%. Methotrexate produced mild nausea and vomiting in 15% of patients and severe vomiting in 10%. The difference between the methotrexate and cisplatin arms was significant, but not between the various cisplatin arms. Renal damage sufficient to affect the serum creatinine was uncommon. Mild (WHO 1–2) effects were seen in 4% of patients in the cisplatin arms and in 2% of the methotre-
This randomised trial was designed to assess whether treatment of advanced or recurrent head and neck cancer with cisplatinum alone could produce a survival advantage over methotrexate alone, and whether the addition of methotrexate or 5-FU to cisplatinum would have any benefit. However, we have also looked at response rates, and at the toxicity of the regimens used. Our response rates are rather poor when compared with the excellent results of others. In particular our response rate of 30% to cisplatinum + 5-FU compares badly with that of Kish et al. (1984), who achieved an overall response rate of 72%, using the same treatment regimen. This can perhaps be explained by the patients’ general condition. In Kish et al.’s study, 80% of patients had a performance status of better than 70 whereas only 63% in our series were in good condition.

There was no significant difference in the response rates of the four groups. However, this is probably a type II error related to the large number of patients needed to produce a significant result if response is the sole criterion.

### Table V Nausea and vomiting

| Regime          | No. of courses | 0 | 1 | 2 | 3 | 4 |
|-----------------|----------------|---|---|---|---|---|
| Cisplatinum     | 94             | 43| 7 | 19| 25| 0 |
| Methotrexate    | 122            | 92| 14| 4 | 12| 0 |
| Cis. + 5-FU     | 101            | 30| 7 | 20| 23| 1 |
| Cis. + MTX      | 96             | 36| 9 | 35| 9 | 7 |

All groups $X^2_1 = 36.3$, $P < 0.001$. Cisplatinum arms $X^2_1 = 2.99$, n.s.

### Table VI Serum creatinine

| Regime          | No. of courses | 0 | 1 | 2 | 3 | 4 |
|-----------------|----------------|---|---|---|---|---|
| Cisplatinum     | 94             | 87| 7 | 0 | 0 | 0 |
| Methotrexate    | 122            | 119| 3 | 0 | 0 | 0 |
| Cis. + 5-FU     | 101            | 98 | 2 | 1 | 0 | 0 |
| Cis. + MTX      | 96             | 93 | 3 | 0 | 0 | 0 |

All groups $X^2_1 = 4.24$, n.s. Cisplatinum arms $X^2_1 = 2.89$, n.s.

### Table VII Haemoglobin

| Regime          | No. of courses | 0 | 1 | 2 | 3 | 4 |
|-----------------|----------------|---|---|---|---|---|
| Cisplatinum     | 94             | 64| 23| 7 | 0 | 0 |
| Methotrexate    | 122            | 110| 7 | 4 | 0 | 1 |
| Cis. + 5-FU     | 101            | 75 | 21| 4 | 0 | 0 |
| Cis. + MTX      | 96             | 68 | 16| 12| 0 | 0 |

All groups $X^2_1 = 18.5$, $P < 0.0001$. Cisplatinum arm $X^2_1 = 2.43$, n.s.

### Table VIII WBC

| Regime          | No. of courses | 0 | 1 | 2 | 3 | 4 |
|-----------------|----------------|---|---|---|---|---|
| Cisplatinum     | 94             | 89 | 5 | 0 | 0 | 0 |
| Methotrexate    | 122            | 116| 3 | 1 | 2 | 0 |
| Cis. + 5-FU     | 101            | 89 | 7 | 5 | 0 | 0 |
| Cis. + MTX      | 96             | 90 | 5 | 1 | 0 | 0 |

All groups $X^2_1 = 4.98$, n.s. Cisplatinum arm $X^2_1 = 3.96$, n.s.

### Table IX Platelets

| Regime          | No. of courses | 0 | 1 | 2 | 3 | 4 |
|-----------------|----------------|---|---|---|---|---|
| Cisplatinum     | 94             | 94 | 0 | 0 | 0 | 0 |
| Methotrexate    | 122            | 119| 1 | 1 | 1 | 0 |
| Cis. + 5-FU     | 101            | 97 | 1 | 3 | 0 | 0 |
| Cis. + MTX      | 96             | 92 | 2 | 2 | 0 | 0 |

All groups $X^2_1 = 4.08$, n.s. Cisplatinum arms $X^2_1 = 3.93$, n.s.

### Table X Treatment regimen

|                  | Cisplatinum       | Methotrexate    | Cis + 5-FU       | Cis + MTX       |
|------------------|-------------------|-----------------|-----------------|----------------|
| Diarrhoea        | 11 (4)            | 1               | 10 (4)          | 12 (6)         |
| Ulceration       | 0                 | 2 (1)           | 2 (2)           | 0              |
| Cutaneous        | 0                 | 0               | 5 (1)           | 0              |
| Pulmonary        | 0                 | 1               | 0               | 0              |
| Pyrexia          | 0                 | 1               | 0               | 0              |
| Allergy          | 0                 | 0               | 1               | 0              |
| Alopecia         | 0                 | 0               | 12 (4)          | 0              |
| Cardiac          | 0                 | 0               | 1               | 0              |
| Consciousness    | 0                 | 0               | 1               | 0              |
| Neuropathy       | 0                 | 0               | 1               | 0              |
| Urea             | 11 (4)            | 3 (3)           | 6 (2)           | 9 (4)          |
| Alkaline phosphatase | 16 (6)    | 13 (6)          | 11 (5)          | 10 (3)         |
| Bilirubin        | 3 (1)             | 0               | 3 (1)           | 0              |
| ALT              | 4 (3)             | 15 (4)          | 7 (2)           | 0              |
| Gamma GT         | 16 (4)            | 25 (8)          | 11 (3)          | 21 (7)         |

The figure in parentheses is the number of patients affected.

**Discussion**

This randomised trial was designed to assess whether treatment of advanced or recurrent head and neck cancer with cisplatinum alone could produce a survival advantage over methotrexate alone, and whether the addition of methotrexate or 5-FU to cisplatinum would have any benefit. However, we have also looked at response rates, and at the toxicity of the regimens used.
Our survival analysis showed that cisplatinum as a single agent was better than methotrexate, and superior also to cisplatinum in combination with 5-FU or methotrexate, although not significantly so. This is contrary to the present climate of opinion, which favours a search for combination regimens. However, no phase III trial has yet demonstrated that regimens employing significant single agents achieve a better survival than single agent cisplatinum.

We have not stratified our patients for prognostic factors. Many statisticians now agree that the benefits of this method are not great (Peto et al., 1976), and that multivariate analysis should be used to identify prognostic factors. Using Cox’s multivariate regression analysis we confirmed the findings of univariate analysis that the only significant factors were Karnofsky performance status and response to chemotherapy. Other factors, such as age, sex, site of the tumour and histological grade were not significant prognostic factors.

It seems that every trial/study of chemotherapy in head and neck cancer produces a different set of significant prognostic factors (Amer et al., 1980; Bertino et al., 1975; Campbell et al., 1987; Sidiak et al., 1989; Vogel & Kaplan, 1979; Wolf et al., 1984), probably because these factors are being confused by other as yet unidentified factors concerned with cell growth and behaviour, for example tumour DNA content (ploidy) (Goldsmith et al., 1986) and oncogene expression (Field et al., 1986).

Methotrexate is clearly a less toxic compound than cisplatinum, although it was surprising to find no increased toxicity in combination regimens compared with cisplatinum alone. The explanation might be that the toxicity categories in the WHO scale are rather liberal. Even if combination regimens do not increase toxicity they inevitably increase cost. This is particularly true of the cisplatinum + 5-FU regimens, which requires five extra days in hospital. This adds a further £1500 (at 1988 prices) to the cost of treatment. In the complete absence of any survival benefit this extra cost cannot be justified.

We did not attempt to assess symptom scores in this group of patients. Most of them had already received extensive treatment and their quality of life is already so low that meaningful differences are very hard to detect and measure. One measure of the quality of life is the proportion of patients surviving beyond six months. There are two reasons for this: first, untreated patients rarely survive beyond this time interval (Morton et al., 1985); and second, six courses of treatment with the recovery period after each course produces a period of 6 months when the quality of life is very low. In order to benefit the patient must survive beyond this period in reasonable condition, and preferably beyond 1 year. Fifty-two per cent of patients randomised to receive cisplatinum survived beyond 6 months, whereas 31% of patients in the methotrexate arm survived beyond this time. Only the patient can decide whether this extra survival is worth the increased morbidity of chemotherapy.

The authors are grateful to the North West Cancer Research Fund for financial support, and to Mrs B. Cowley and Mrs J. Deeprose for the typing.

References

AMER, M.H., IZBICKI, R.M., VAIKIEVICIUS, V.K. & AL-SARRAF, M. (1980). Combination chemotherapy with cis-diaminedichloroplatinum, oncovin and bleomycin (COB) in advanced head and neck cancer. Cancer, 45, 217.
BERTINO, J.R., BOSTON, B. & CAPIZZI, R.L. (1975). The role of chemotherapy in the management of cancer of the head and neck: a review. Cancer, 36, 752.
CAMPBELL, J.B., DORMAN, E.B., STELL, P.M. & 8 others (1987). Factors predicting response of end-stage squamous cell carcinoma of the head and neck to cisplatin. Clin. Otolaryngol., 12, 167.
COX, D.R. (1972). Regression models and life tables. J. R. Stat. Soc. Ser. B, 34, 187.
DECKER, D.A., BELLICKMAN, A., JACOB, I. & 5 others (1983). Adjuvant chemotherapy with cis-diaminedichloroplatinum II and 120 hours infusion of 5-fluorouracil in stage III and IV squamous carcinoma of the head and neck. Cancer, 51, 1353.
FIELD, J.K., LAMOTHE, A. & SPANDIDOS, D.A. (1986). Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res., 6, 595.
GOLDSMITH, M.M., CRESSON, D.S., POSTMA, D.S., ASKIN, M.D. & PILLSBURY, H.C. (1986). Significance of ploidy in laryngeal cancer. Am. J. Surg., 152, 396.
HONG, W.K., SCHAFFER, S., ISELL, B. & 11 others (1983). A prospective randomized trial of methotrexate versus cisplatinum in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer, 52, 206.
JACOB, C. (1980). The role of cisplatin in the treatment of recurrent head and neck cancer. In Cisplatinum: Current Status and New Developments, Prestyko, A.W., Crooke, S.T. & Carter, S.K. (eds) p.423. Academic Press: London.
JACOBS, C., MEYERS, F., HENDRICKSON, C., KOHLER, M. & CARTER, S. (1983). A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer, 52, 1563.
KAPLAN, E.L. & MEIER, P. (1985). Nonparametric estimation from incomplete observations. J. Am. Stat. Assc., 53, 457.
KARNOFSKY, D.A. & BUCKENALL, J.H. (1949). The clinical evaluation of chemotherapeutic agents. In Evaluation of Chemotherapeutic Agents in Cancer, Maceled, M.C. (ed) p.191. Columbia University Press: New York.
KISH, M.S., WEAVER, A., JACOBS, J., CUMMINGS, G. & AL-SARRAF, M. (1984). Cisplatinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer, 53, 1819.
KISH, J., ENSLEY, J., WEAVER, A. & 3 others (1985). A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer, 56, 2740.
MILLER, A.B., HOOOSTRATEN, B., STAQUET, M. & WINKLER, A. (1981). Reporting results of cancer treatment. Cancer, 47, 207.
MORTON, R.P., RUGMAN, F., STELL, P.M. & 5 others (1983). Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck, a randomized factorial phase III controlled trial. Cancer Chemother. Pharmacol., 15, 283.
MUGGIA, F.M., ROZENCZWEIG, M. & LOUIE, A.C. (1980). Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg., 2, 196.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1976). Designs and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 34, 585.
SIDIACK, M.Z., CAMPBELL, J.B., STELL, P.M. & 6 others (1989). Induction VBM plus radiotherapy, versus radiotherapy alone for advanced head and neck cancer. Clin. Otolaryngol., 14, 17.
VOGEL, S.E. & KAPLAN, B.H. (1979). Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin and cis-diaminedichloroplatinum II in an effective outpatient schedule. Cancer, 44, 26.
WITTES, R., HELLER, K., RANDOLPH, V. & 8 others (1979). Cis-dichlorodiammineplatinum (II) based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat. Rep., 63, 1533.
WOLF, G.T., MAKUCH, R.W. & BAKER, S.R. (1984). Predictive factors for tumour response to preoperative chemotherapy in patients with head and neck squamous carcinoma. Cancer, 54, 2869.
UICC (1987). Classification of Malignant Tumours, 4th edn. Springer-Verlag: Berlin.